Sign In
Free Newsletter
Baltimore biopharm hires neuroscience veteran Mohs as VP
//December 8, 2015
Baltimore-based biopharmaceutical company AgeneBio has appointed Richard Mohs as vice president of clinical development.
Mohs has more than 30 years of experience in neuroscience clinical development and led Eli Lilly’s Phase 3 development team for Alzheimer’s disease drug candidates solanezumab and semagacesta, AgeneBio noted in a statement Tuesday.
Most recently, Mohs served as Eli Lilly’s vice president for neuroscience early clinical development and distinguished research fellow within Lilly Research Laboratories, where he led a clinical development team targeting Alzheimer’s disease or other neurodegenerative diseases, pain, depression or schizophrenia.
